drugset
drugset / Trial / NCT05833139

A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood

NCT05833139 ↗

Phase 1 Completed 16 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of multiple doses of the strong CYP3A inhibitor and recommended P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of a single dose of zongertinib in plasma following oral administration.

Timeline

Start
2023-04-14
Primary completion
2023-06-12
Completion
2023-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Zongertinib Small molecule 15 mg Oral

Indications

No indication recorded.